Publications by authors named "G Carolo"
The reactivation of hepatitis B virus (HBVr) in patients undergoing pharmacological immunosuppression is a potentially fatal clinical event that may occur in patients with overt or occult HBV infection. The risk of HBVr is mainly determined by the type of immunosuppressive therapy and the HBV serologic profile, with a higher risk in patients positive for the hepatitis B surface antigen (HBsAg), and a lower risk in HBsAg-negative/antibodies to core antigen-positive subjects. Notably, a considerable proportion of patients experiencing HBVr showed a high degree of variability of the HBV S gene, possibly leading to immune escape mutants.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the effectiveness and safety of the drug combination sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for treating HCV patients who previously failed direct-acting antivirals (DAAs) in a real-life setting across 27 centers in Northern Italy.
- A total of 179 patients were treated, with a 91% overall success rate achieving sustained viral response (SVR12); common issues included cirrhosis and previous liver cancer as predictors of treatment failure, while side effects were relatively low.
- The findings support that SOF/VEL/VOX is a highly effective and safe option for retreating
Background & Aims: Direct-acting antiviral agents (DAAs) are safe and effective in patients with hepatitis C. Conflicting data were reported on the risk of hepatocellular carcinoma (HCC) during/after therapy with DAAs. The aim of this study was to evaluate the incidence of newly diagnosed HCC and associated risk factors in patients with advanced hepatitis C treated with DAAs.
View Article and Find Full Text PDF